IMC Chicago
RXRX icon

IMC Chicago’s Recursion Pharmaceuticals RXRX Stock Holding History

IMC Chicago’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-66,215
Closed -$328K – 4380
2025
Q3 		$323K Buy
+66,215
New +$348K ﹤0.01% 3383
2025
Q2 		– Sell
-183,040
Closed -$899K – 3551
2025
Q1 		$968K Buy
+183,040
New +$1.33M ﹤0.01% 2291

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

IMC Chicago's RXRX Position: Q4 2025 in Review

IMC Chicago sold out of Recursion Pharmaceuticals (RXRX) in Q4 2025, closing a stake of 66,215 shares — an estimated $328K sold.

IMC Chicago first reported a position in RXRX in Q1 2025 and held it in 2 quarters. The position peaked at $968K in Q1 2025. 333 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

  • IMC Chicago reported no remaining Recursion Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • IMC Chicago sold 66,215 Recursion Pharmaceuticals shares in Q4 2025, an estimated $328K.
  • IMC Chicago first reported a position in Recursion Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • IMC Chicago's Recursion Pharmaceuticals position peaked at $968K in Q1 2025.
  • 333 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on IMC Chicago's 13F filing for Q4 2025, filed 29 Jan 2026.